Cancer & Tumors3,815 citations
Radiat Res 147(4):495-500, 1997
Bioeffects Seen
Authors not listed · 1997
Insufficient information to determine key finding.
Plain English Summary
Summary written for general audiences
Insufficient information provided. The study record contains only a journal citation (Radiat Res 147(4):495-500, 1997) and indicates it is a review article, but no title, abstract, or specific study details are included to determine the topic or findings.
Why This Matters
This appears to be a review article from Radiation Research, a peer-reviewed journal, but without the full title or abstract, the specific subject matter and relevance to EMF health effects cannot be assessed.
Exposure Information
Specific exposure levels were not quantified in this study.
Cite This Study
Unknown (1997). Radiat Res 147(4):495-500, 1997.
Show BibTeX
@article{radiat_res_1474495_500_1997_ce3077,
author = {Unknown},
title = {Radiat Res 147(4):495-500, 1997},
year = {1997},
doi = {10.1038/s41572-020-00224-3},
}Quick Questions About This Study
Head and neck squamous cell carcinoma primarily affects the mucosal lining of the oral cavity, pharynx (throat), and larynx (voice box). These are the same tissue regions that receive direct electromagnetic field exposure from cell phones during calls.
HPV infection is increasingly responsible for pharynx cancers, while tobacco and alcohol remain primary causes for oral cavity and larynx cancers. This shift has created two distinct disease categories: HPV-positive and HPV-negative head and neck cancers.
Despite evidence of cellular changes progressing through various stages of abnormality, most patients are diagnosed with advanced-stage disease without clinically obvious pre-cancerous lesions. Early detection remains challenging in these anatomical regions.
Treatment typically involves multiple approaches: surgery followed by combined chemotherapy and radiation for oral cancers, and primary chemoradiotherapy for throat and voice box cancers. Newer immunotherapy drugs are also approved for advanced cases.
The past decade of genetic research has revealed new therapeutic targets and led to FDA approval of immune checkpoint inhibitors like pembrolizumab and nivolumab. Scientists are working to identify biomarkers for more personalized, effective treatments.